Maria Elena Ortiz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Maria Elena Ortiz has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Alexia Hermanny
Human Reproduction Unit, Department of Obstetrics and Gynecology, School of Medicine, University of Campinas (UNICAMP), 13084-971 Campinas, SP, Brazil
1 shared publication - Carlos Simón
Carlos Simon Foundation, Valencia, Spain; INCLIVA Biomedical Research Institute, Valencia, Spain; Pediatrics, Obstetrics and Gynecology Department, Faculty of Medicine, University of Valencia, Valencia, Spain; Department of Obstetrics and Gynecology, BIDMC, Harvard University, Boston, Massachusetts
1 shared publication - Daniel Hyam Wreschner
Department of Cell Research and Immunology, Tel Aviv University, Ramat Aviv, Israel
1 shared publication - Francisco Fazano
Human Reproduction Unit, Department of Obstetrics and Gynecology, School of Medicine, University of Campinas (UNICAMP), 13084-971 Campinas, SP, Brazil
1 shared publication - Horacio B Croxatto
Departamento de Biología, Facultad de Química y Biología, Universidad de Santiago de Chile, Santiago, Chile
1 shared publication - Horacio Croxatto1 shared publication
Latest Publications
- Open Access
- 30 January 2012
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 10 (1) , 8
In vitro assessment of some sperm function following exposure to levonorgestrel in human fallopian tubes
The mechanism of action of levonorgestrel (LNG) as emergency contraception (EC) remains a subject of debate and its effect on sperm function has been only partially explained. The aim of this study was to assess whether LNG at a similar dose to those found in serum following oral intake for EC could affect spermatozoa when exposed to human fallopian tubes in vitro.
- 30 January 2012
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 10 (1) , 8
Open AccessIn vitro assessment of some sperm function following exposure to levonorgestrel in human fallopian tubes
The mechanism of action of levonorgestrel (LNG) as emergency contraception (EC) remains a subject of debate and its effect on sperm function has been only partially explained. The aim of this study was to assess whether LNG at a similar dose to those found in serum following oral intake for EC could affect spermatozoa when exposed to human fallopian tubes in vitro.
- Open Access
- 1 August 2006
- Published by Universidad de Costa Rica in Población y Salud en Mesoamérica
- Vol. 4 (2)
Cómo y cuando el levonorgestrel previene el embarazo cuando se administra como anticonceptivo de emergencia
La anticoncepción hormonal de emergencia (AHE) es uno de los pocos recursos que la mujer puede usar para prevenir un embarazo no deseado después de haber tenido una relación sexual en la que no usó método anticonceptivo o el que usó presentó una falla. Actualmente, el método preferido para la AHE es la píldora que contiene solamente levonorgestrel (LNG). Según la OMS, puede prevenir embarazos si se usa hasta 120 horas después del acto sexual, pero su eficacia disminuye drásticamente desde 85% a 31% mientras más se posterga su administración. La introducción de la AHE ha generado controversia en muchos países latinoamericanos por la percepción errónea de que induce aborto y la oposición de los sectores más conservadores de la sociedad que temen que favorezca la promiscuidad. Con el propósito de dar a conocer la evidencia científica producida por las investigaciones diseñadas para dilucidar como el LNG previene el embarazo cuando se administra como AHE, y su correcta interpretación, este artículo analiza críticamente dichos estudios y explica además en que circunstancias este método no logra prevenir el embarazo. El conjunto de la evidencia indica que LNG previene el embarazo solamente cuando impide la fecundación y descarta que el prevenga el embarazo interfiriendo con la implantación del embrión, por lo que la creencia de que es abortivo no tiene sustento científico.
- 1 August 2006
- Published by Universidad de Costa Rica in Población y Salud en Mesoamérica
- Vol. 4 (2)
Open AccessCómo y cuando el levonorgestrel previene el embarazo cuando se administra como anticonceptivo de emergencia
La anticoncepción hormonal de emergencia (AHE) es uno de los pocos recursos que la mujer puede usar para prevenir un embarazo no deseado después de haber tenido una relación sexual en la que no usó método anticonceptivo o el que usó presentó una falla. Actualmente, el método preferido para la AHE es la píldora que contiene solamente levonorgestrel (LNG). Según la OMS, puede prevenir embarazos si se usa hasta 120 horas después del acto sexual, pero su eficacia disminuye drásticamente desde 85% a 31% mientras más se posterga su administración. La introducción de la AHE ha generado controversia en muchos países latinoamericanos por la percepción errónea de que induce aborto y la oposición de los sectores más conservadores de la sociedad que temen que favorezca la promiscuidad. Con el propósito de dar a conocer la evidencia científica producida por las investigaciones diseñadas para dilucidar como el LNG previene el embarazo cuando se administra como AHE, y su correcta interpretación, este artículo analiza críticamente dichos estudios y explica además en que circunstancias este método no logra prevenir el embarazo. El conjunto de la evidencia indica que LNG previene el embarazo solamente cuando impide la fecundación y descarta que el prevenga el embarazo interfiriendo con la implantación del embrión, por lo que la creencia de que es abortivo no tiene sustento científico.
- Open Access
- 30 January 2003
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 1 (1) , 2
Transmembrane and truncated (SEC) isoforms of MUC1 in the human endometrium and Fallopian tube
The cell surface mucin MUC1 is expressed by endometrial epithelial cells with increased abundance in the secretory phase of the menstrual cycle, when it is found both at the apical cell surface and in secretions. This suggests the presence of a maternal cell surface glycoprotein barrier to embryo implantation, arising from the anti-adhesive property of MUC1. In previous work, we demonstrated alternatively spliced MUC1 variant forms in tumour cells. The variant MUC1/SEC lacks the transmembrane and cytoplasmic sequences found in the full-length variant. We now show that MUC1/SEC mRNA is present in endometrial carcinoma cell lines, endometrial tissue and primary cultured endometrial epithelial cells. The protein can be detected using isoform-specific antibodies in uterine flushings, suggesting release from endometrium in vivo. However, on the basis of immunolocalisation studies, MUC1/SEC also remains associated with the apical epithelial surface both in tissue and in cultured cells. Transmembrane MUC1 and MUC1/SEC are both strikingly localised to the apical surface of tubal epithelium. Thus MUC1 may contribute to the anti-adhesive character of the tubal surface, inhibiting ectopic implantation. The mechanism by which this barrier is overcome in endometrium at implantation is the subject of ongoing investigation.
- 30 January 2003
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 1 (1) , 2
Open AccessTransmembrane and truncated (SEC) isoforms of MUC1 in the human endometrium and Fallopian tube
The cell surface mucin MUC1 is expressed by endometrial epithelial cells with increased abundance in the secretory phase of the menstrual cycle, when it is found both at the apical cell surface and in secretions. This suggests the presence of a maternal cell surface glycoprotein barrier to embryo implantation, arising from the anti-adhesive property of MUC1. In previous work, we demonstrated alternatively spliced MUC1 variant forms in tumour cells. The variant MUC1/SEC lacks the transmembrane and cytoplasmic sequences found in the full-length variant. We now show that MUC1/SEC mRNA is present in endometrial carcinoma cell lines, endometrial tissue and primary cultured endometrial epithelial cells. The protein can be detected using isoform-specific antibodies in uterine flushings, suggesting release from endometrium in vivo. However, on the basis of immunolocalisation studies, MUC1/SEC also remains associated with the apical epithelial surface both in tissue and in cultured cells. Transmembrane MUC1 and MUC1/SEC are both strikingly localised to the apical surface of tubal epithelium. Thus MUC1 may contribute to the anti-adhesive character of the tubal surface, inhibiting ectopic implantation. The mechanism by which this barrier is overcome in endometrium at implantation is the subject of ongoing investigation.